LB Pharmaceuticals Inc
LBRX
$18.76
$0.271.46%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | |||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | ||
| Total Other Revenue | -- | -- | -- | ||
| Total Revenue | -- | -- | -- | ||
| Cost of Revenue | -- | -- | -- | ||
| Gross Profit | -- | -- | -- | ||
| SG&A Expenses | -47.83% | 23.73% | 174.09% | ||
| Depreciation & Amortization | -- | -- | -- | ||
| Other Operating Expenses | -- | -- | -- | ||
| Total Operating Expenses | -67.38% | -80.08% | -68.16% | ||
| Operating Income | 67.38% | 80.08% | 68.16% | ||
| Income Before Tax | 74.92% | 81.63% | 68.50% | ||
| Income Tax Expenses | -- | -- | -- | ||
| Earnings from Continuing Operations | 74.92% | 81.63% | 68.50% | ||
| Earnings from Discontinued Operations | -- | -- | -- | ||
| Extraordinary Item & Accounting Change | -- | -- | -- | ||
| Minority Interest in Earnings | -- | -- | -- | ||
| Net Income | 74.92% | 81.63% | 68.50% | ||
| EBIT | 67.38% | 80.08% | 68.16% | ||
| EBITDA | 67.88% | 80.37% | 68.62% | ||
| EPS Basic | 99.78% | 68.77% | 68.77% | ||
| Normalized Basic EPS | -- | -- | 70.65% | ||
| EPS Diluted | 99.78% | 68.77% | 68.77% | ||
| Normalized Diluted EPS | -- | -- | 70.65% | ||
| Average Basic Shares Outstanding | -- | -- | 0.88% | ||
| Average Diluted Shares Outstanding | 10,035.86% | 0.88% | 0.88% | ||
| Dividend Per Share | -- | -- | -- | ||
| Payout Ratio | -- | -- | -- | ||